Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ATF4 | P18848 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 9/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RHOC | P08134 | 2/20 | 0.36 |
| ▸ | RHOA | P61586 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24998294 | 0.94 | CYP3A4 (0.45) | MEN1KMT2AATF4PTGESFAAH | |
| SCHEMBL24998141 | 0.90 | FAAH (0.43) | ATF4PTGESFAAHLMNAL3MBTL1 | |
| SCHEMBL24997345 | 0.90 | ATF4 (0.43) | KMT2AATF4PTGESPTGS2 | |
| SCHEMBL24997259 | 0.83 | ATF4 (0.43) | MEN1KMT2AATF4EPHX2FAAH | |
| SCHEMBL24997261 | 0.77 | ATF4 (0.43) | ATF4LMNARHOCRHOA | |
| SCHEMBL30053354 | 0.77 | ATF4 (0.43) | ATF4LMNARHOCRHOA | |
| SCHEMBL24998143 | 0.77 | FAAH (0.41) | ATF4FAAHKDM4E | |
| SCHEMBL24997981 | 0.77 | ATF4 (0.40) | KMT2AATF4LMNASCN9A | |
| SCHEMBL30053049 | 0.77 | ATF4 (0.40) | KMT2AATF4LMNASCN9A | |
| SCHEMBL29987741 | 0.77 | ATF4 (0.53) | ATF4PTGESPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230042881-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042881-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, ATF1, DDIT3 | MEN1 4499/4885KMT2A 4558/4885ATF4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.